richwolol

Looking for the Biotech Breakout

How can you report the pending breakout of Biotechs, including BIIB but not ELN. The drug Tysabri is co-owned (50%) owned by each company

Time to Buy Elan?

It is refreshing to read an accurate historical doocument about Elan and their trials and tribulations. Also refreshing to hear the author tell what I an many others know: Tysabri is the most effective drug to combat the ravages of MS. What could have been emphasized and was not is that when taken as per the label requirements the chances of contracting PML are close to Nil. In these latest two instances, I beleive it would be extremely helpful if Elan hired a few well seasoned investigators to examine the medical history. Since both of these PML sufferers are from Europe where socialized medicine is practiced, it should be quite simple to determine what drugs these persons imbibed. There must be rocords of whatever drugs have been dispensed. I have already heard that patient number one had a history of taking Azathioprine, one of the drugs forbidden to have taken or perhaps still taking while having Tysabri infused. With patient number 2, I wonder what has taken so long to get a history of what drugs he was imbibing. Making light of their findings will make prescribing neuros more careful on who they put onto Tysabri. Elan needs the services of a old retired NYPD detective to work with the boatload of scientists they already have. r

21 Airline Stocks to Keep You Flying High This Summer

The writer of the article has an obvious bias (at least he admits to being long on JBLU). He failed to even mention Airtran (AAI) that has newer more economical airplanes and a much lower PE ratio. They also move one person one mile at a lower cost then any airline operating in the US. If anyone is poised to leap out if and when the climate changes, it will be Air Tran at a much higher rate then JBlU. Granted JBLU, gets a lot of hype, good markeeting and is in a good position, but no match compared to Air Tran.